泰地唑胺对革兰阳性球菌的体外抗菌活性研究

doi:10.3969/j.issn.1673-8640.2019.05.009

摘要/Abstract

摘要：

目的研究革兰阳性球菌对新型噁唑烷酮类抗菌药物——泰地唑胺的敏感性,并探讨泰地唑胺不敏感菌株的耐药机制。方法收集1 069株革兰阳性球菌[耐甲氧西林金黄色葡萄球菌（MRSA）202株、甲氧西林敏感金黄色葡萄球菌（MSSA）294株、凝固酶阴性葡萄球菌（CoNS）115株、粪肠球菌206株、屎肠球菌55株、无乳链球菌159株和咽峡炎链球菌群菌株38株]非重复临床分离株。采用微量肉汤稀释法检测所有菌株对泰地唑胺和利奈唑胺的最小抑菌浓度（MIC）,分析泰地唑胺和利奈唑胺MIC值的差异,比较2种抗菌药物的抗菌活性;采用聚合酶链反应（PCR）检测泰地唑胺/利奈唑胺不敏感菌株的耐药基因。结果所有葡萄球菌（MIC≤0.5 μg/mL）、屎肠球菌（MIC≤0.5 μg/mL）和链球菌（MIC≤0.25 μg/mL）均对泰地唑胺敏感,粪肠球菌对泰地唑胺的敏感率为94.7%,检测出11株泰地唑胺和利奈唑胺均不敏感粪肠球菌（泰地唑胺MIC=1 μg/mL,利奈唑胺MIC=8 μg/mL）。泰地唑胺的抗菌活性是利奈唑胺的4~8倍。泰地唑胺/利奈唑胺不敏感菌株只携带optrA基因。结论泰地唑胺作为治疗革兰阳性球菌感染的一种新型抗菌药物,具有较大的应用价值,但携带optrA基因的泰地唑胺不敏感肠球菌值得关注。

关键词: 泰地唑胺, 体外抗菌活性, 革兰阳性球菌, 噁唑烷酮类抗菌药物

Abstract:

Objective To investigate the drug susceptibilities of a novel oxazolidinone antibiotic,tedizolid,against clinical Gram-positive cocci,and to investigate the drug resistance mechanism in non-tedizolid susceptible isolates. Methods A total of 1 069 clinical Gram-positive cocci were collected. The isolates included 202 isolates of methicillin-resistant Staphylococcus aureus （MRSA）,294 isolates of methicillin-susceptible Staphylococcus aureus （MSSA）,115 isolates of coagulase-negative Staphylococcus,206 isolates of Enterococcus faecalis,55 isolates of Enterococcus faecium,159 isolates of Streptococcus agalactiae and 38 isolates of Streptococcus anginosus. The minimum inhibitory concentrations （MIC） of tedizolid and linezolid were determined by broth microdilution method and analyzed to clarify the difference of in vitro activities of them. Polymerase chain reaction （PCR） was performed to determine the drug resistance genes in tedizolid/linezolid non-susceptible isolates. Results All isolates of Staphylococcus （MIC≤0.5 μg/mL）,Enterococcus faecium （MIC≤0.5 μg/mL） and Streptococcus （MIC≤0.25 μg/mL） were susceptible to tedizolid. The susceptibility rate of Enterococcus faecalis to tedizolid was 94.7%. Totally,11 tedizolid and linezolid non-susceptible isolates （tedizolid MIC=1 μg/mL,linezolid MIC=8 μg/mL） were found,which were positive for the novel oxazolidinone resistance gene, optrA. Tedizolid revealed 4-8-fold more effective than linezolid. Conclusions Tedizolid is a novel antibiotic for treating Gram-positive cocci infection,however,its drug resistance mediated by optrA in Enterococcus should be concerned.

Key words: Tedizolid, In vitro susceptibility, Gram-positive coccus, Oxazolidinone

中图分类号:

R446.1

林文, 黄凯峰, 杨涵, 何春燕, 陈雯静, 舒文, 汤荣, 易峻文, 刘庆中. 泰地唑胺对革兰阳性球菌的体外抗菌活性研究[J]. 检验医学, 2019, 34(5): 428-432.

LIN Wen, HUANG Kaifeng, YANG Han, HE Chunyan, CHEN Wenjing, SHU Wen, TANG Rong, YI Junwen, LIU Qingzhong. Activities of tedizolid in vitro against clinical Gram-positive cocci[J]. Laboratory Medicine, 2019, 34(5): 428-432.

图/表 2

参考文献 27

[1]	MOELLERING R C.Tedizolid:a novel oxazolidinone for Gram-positive infections[J]. Clin Infect Dis,2014,58(Suppl 1):S1-S3.
[2]	ARIAS C A,MURRAY B E.The rise of the Enterococcus:beyond vancomycin resistance[J]. Nat Rev Microbiol,2012,10(4):266-278.
[3]	SONG J H.Advances in pneumococcal antibiotic resistance[J]. Expert Rev Respir Med,2013,7(5):491-498.
[4]	SONG J H,HSUEH P R,CHUNG D R,et al.Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries:an ANSORP study[J]. J Antimicrob Chemother, 2011,66(5):1061-1069.
[5]	TSAI H Y,LIAO C H,CHEN Y H,et al.Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline,daptomycin,and linezolid and molecular epidemiology of the isolates:results from the tigecycline in vitro surveillance in Taiwan (TIST) study,2006 to 2010[J]. Antimicrob Agents Chemother,2012,56(6):3402-3405.
[6]	CHEN K H,HUANG Y T,LIAO C H,et al.In vitro activities of tedizolid and linezolid against Gram-positive cocci associated with acute bacterial skin and skin structure infections and pneumonia[J]. Antimicrob Agents Chemother,2015,59(10):6262-6265.
[7]	CROTTY M P,KREKEL T,BURNHAM C A,et al.New Gram-positive agents:the next generation of oxazolidinones and lipoglycopeptides[J]. J Clin Microbiol,2016,54(9):2225-2232.
[8]	BENSACI M,SAHM D.Surveillance of tedizolid activity and resistance:in vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe[J]. Diagn Microbiol Infect Dis,2017,87(2):133-138.
[9]	BARBER K E,SMITH J R,RAUT A,et al.Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin,daptomycin or linezolid[J]. J Antimicrob Chemother,2016,71(1):152-155.
[10]	LI S,GUO Y,ZHAO C,et al.In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia,skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China[J]. J Med Microbiol,2016,65(10):1215-1224.
[11]	RAJAN S.Skin and soft-tissue infections:classifying and treating a spectrum[J]. Cleve Clin J Med,2012,79(1):57-66.
[12]	SHORR A F,LODISE T P,COREY G R,et al.Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections[J]. Antimicrob Agents Chemother,2015,59(2):864-871.
[13]	MORAN G J,FANG E,COREY G R,et al.Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2):a randomised,double-blind,phase 3,non-inferiority trial[J]. Lancet Infect Dis,2014,14(8):696-705.
[14]	DAS D,TULKENS P M,MEHRA P,et al.Tedizolid phosphate for the management of acute bacterial skin and skin structure infections:safety summary[J]. Clin Infect Dis,2014,58(Suppl 1):S51-S57.
[15]	BURDETTE S D,TROTMAN R.Tedizolid:the first once-daily oxazolidinone class antibiotic[J]. Clin Infect Dis,2015,61(8):1315-1321.
[16]	WOODFORD N,LIVERMORE D M.Infections caused by Gram-positive bacteria:a review of the global challenge[J]. J Infect,2009,59(Suppl 1):S4-S16.
[17]	Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically[S]. M07-A10,CLSI,2015.
[18]	Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. M100-S26,CLSI,2016.
[19]	KEHRENBERG C,SCHWARZ S.Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates[J]. Antimicrob Agents Chemother,2006,50(4): 1156-1163.
[20]	WANG Y,LV Y,CAI J,et al.A novel gene,optrA,that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin[J]. J Antimicrob Chemother,2015,70(8):2182-2190.
[21]	BOURGEOIS-NICOLAOS N,MASSIAS L,COUSON B,et al.Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo[J]. J Infect Dis,2007,195(10):1480-1488.
[22]	ZHANEL G G,LOVE R,ADAM H,et al.Tedizolid:a novel oxazolidinone with potent activity against multidrug-resistant Gram-positive pathogens[J]. Drugs,2015,75(3):253-270.
[23]	FERRÁNDEZ O,URBINA O,GRAU S. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections[J]. Drug Des Devel Ther,2016,11:65-82.
[24]	BAEK J Y,KANG C I,KIM S H,et al.In vitro activity of tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian countries[J]. Diagn Microbiol Infect Dis,2016,85(2):218-220.
[25]	BIEDENBACH D J,BOUCHILLON S K, JOHNSON B,et al.In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries,Australia,New Zealand,and China[J]. Eur J Clin Microbiol Infect Dis,2016,35(12):1933-1939.
[26]	HE T,SHEN Y,SCHWARZ S,et al.Genetic environment of the transferable oxazolidinone/phenicol resistance gene optrA in Enterococcus faecalis isolates of human and animal origin[J]. J Antimicrob Chemother,2016,71(6):1466-1473.
[27]	CAI J,WANG Y,SCHWARZ S,et al. Enterococcal isolates carrying the novel oxazolidinone resistance gene optrA from hospitals in Zhejiang,Guangdong,and Henan,China,2010-2014[J]. Clin Microbiol Infect,2015,21(12):1095.e1-e4.